GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GenMont Biotech 3164.TW · TWD

Health Care · Taiwan Stock Exchange · 🇹🇼 Taiwan

Compare

16.65

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GenMont Biotech

Its shares trade on Taiwan Stock Exchange under the ticker 3164.TW. It has been listed since 12 June 2003. In the fiscal year to 31 December 2025, it reported revenue of TWD 401.2m and net income of TWD 57.2m. At that date it held total assets of TWD 1.67bn and shareholders' equity of TWD 1.33bn.

Genmont Biotech Inc. engages in the research development, manufacturing, and selling of probiotic supplements. The company is headquartered in Tainan, Tainan. The company went IPO on 2003-06-12. The firm's major products include lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus fermentum, lactobacillus salivarius, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus brevis, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus johnsonii and others. The Company’s products are applied to enhance human immunity against dust allergy and digestive system health care. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Jun 2003

Leadership

Pay as last reported

  • Mr. Gende ChenChairman of the Board, since 2005TWD 4.2m
  • Weimin ChenChief Operating Officer
  • Ms. Yujin ChenDeputy General Manager, since 2008
  • Zhaotang HuangManager of Accounting
  • Mr. Guojie HuangDirector
  • Yixiong LinDirector
  • Mr. Dehui YangDirector
  • Mr. Chuanzhen ZhuoDirector
  • Mr. Zhibin GaoIndependent Director
  • Mr. Tse-Jen HuangIndependent Director
  • Mr. Qinglong LinIndependent Director
  • Mr. Jyh-Feng LuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • GenMont Biotech Inc. focuses on probiotic supplements for immunity and digestive health.
  • Tainan serves as a strategic hub for biotechnology research and development in Taiwan.
  • The company's diverse product range includes 12 specific lactobacillus strains.

Weaknesses

  • The company's domestic market focus limits international expansion opportunities.
  • Lack of detailed information on overseas market share and growth rates.
  • No mention of R&D investment in the provided facts.

Opportunities

  • Growing global demand for probiotic supplements in the Health Care sector.
  • Expansion into new markets for lactobacillus-based products.
  • Increased consumer interest in digestive health solutions.

Threats

  • Competition from other biotechnology firms in Taiwan's Health Care sector.
  • Regulatory challenges in international markets for probiotic products.
  • Economic downturns affecting consumer spending on health supplements.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.